Theralase Technologies Inc. (TSX VENTURE:TLT) announces revolutionary results of a pre-clinical study of its patented photodynamic compounds (PDCs) and their ability, when used with Theralase lasers, to destroy breast cancer cells. Theralase plans to submit results to the US Food and Drug Administration and Health Canada, as part of its collaborative work with Virginia Tech.

The electrophysiology team at the Montreal Heart Institute (MHI) recently performed the first implantation of a new type of cardiac pacemaker (Accent RF™) in Canada. This landmark procedure was carried out on October 22, 2009 by Drs. Bernard Thibault and Peter Guerra. Both are cardiologists, electrophysiologists at the MHI and professors at the Université de [...]

VentriPoint Diagnostics Ltd. (”VentriPoint” or the “Corporation”) (TSX VENTURE:VPT) is pleased to announce that it has received approval to CE Mark its VentriPoint Medical System (VMS) which generates critical heart measurements from 2D ultrasounds in a rapid, accurate and inexpensive manner not currently available. Rapid and accurate right ventricle measurements is essential for assessment of [...]

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. Health Canada’s performance target for the completion of review and a decision is within [...]

On November 10, 2009 at 12:00 noon EST Health Minister Leona Aglukkaq and National Chief of the Assembly of First Nations (AFN) Shawn Atleo will co-host a Virtual Summit on H1N1 preparedness for First Nations communities.